Desmoid Tumor Research Foundation

This is your research
Your dollars fund research that impacts the whole desmoid tumor community. Make a difference!
Your donations make a difference!
Donate Today »

#soliloquy-container-16209{opacity:1}#soliloquy-container-16209 li > .soliloquy-caption{display:none}#soliloquy-container-16209 li:first-child > .soliloquy-caption{display:block}

International Research Workshop for Medical Professionals

Learn more »

Make It Possible!
Join our year-end campaign to help achieve our 2020 research initiative
Join Today

#soliloquy-container-16235{opacity:1}#soliloquy-container-16235 li > .soliloquy-caption{display:none}#soliloquy-container-16235 li:first-child > .soliloquy-caption{display:block} make_it_possible_rocket_slide

International Research Workshop for Medical Professionals

Learn more »

For the latest DTRF news sign up for one of our newsletters to stay informed.

FOR PATIENTS

FOR PHYSICIANS

First-of-its-kind global consensus paper on desmoid tumor treatment published!

Read patient booklet.

Phase 3 Nirogacestat Trial

Phase I Tegavivint Trial

2019 DTRF Patient Meeting Presentations

Int’l DTRF Desmoid Tumor Research Workshop

DFC- Desmoid Tumour Foundation of Canada

ANNOUNCEMENTS

First-of-its-kind global consensus paper on desmoid tumor treatment published!

Read patient booklet.

Paper published on DTRF’s PRO Tool

Update on DTRF Mouse Model project

To Be Announced: Pediatric clinical trial for nirogacestat. Learn about adult clinical trial.

New England Journal of Medicine Article “Sorafenib for Advanced and Refractory Desmoid Tumors” and DTRF Press Release

FDA Approves Fast Track Designation for NirogacestatIn anticipation of the drug’s phase III trial

Tegavivint Trial LaunchesIterion Therapeutics, formerly known as Beta Cat Pharmaceuticals, today announced that it has initiated a multi-center Phase I clinical study of Tegavivint

Abstract for Phase II Pazopanib TrialDT are a group of locally aggressive tumors of fibroblastic origin that can lead

ASCO Presentation for Phase II Pazopanib TrialPazopanib versus IV methotrexate/vinblastine in
adult patients

DTRF’s 2019 Grant AwardsGerlinde Wernig, MD, Assistant Professor of Pathology, Standford Univesity School

2019 DTRF Patient Meeting Presentations

Int’l DTRF Desmoid Tumor Research WorkshopSave the date for the Sept 25, 2020 DTRF International Desmoid Tumor Research Workshop

Desmoid Tumour Foundation of CanadaThey donated $100,000 to DTRF research initiatives in 2019!

Click here for archive of UPDATES

On Saturday, Sept. 21st, in Philadelphia, PA, DTRF held its Annual Patient Meeting. This event educates and empowers patients and caregivers by teaching them about the latest research & treatment options available. Save the date for our 2020 events on Sept. 26th & 27th! Learn more »

Make a difference in the lives of many by joining us at one of our fundraising events. Or better yet, organize one of your own! Events are hosted by patients, caregivers and others committed to a cure for desmoid tumors. Learn more »

DTRF encourages you to join the DTRF Patient Registry in order to facilitate research efforts. With access to your experience as a patient, researchers will be able to continue learning and making new discoveries in the field of desmoid tumors. If you have ever had a desmoid tumor, you can participate.

Published paper »

Learn more »

Because desmoid tumors are so rare, they are often misunderstood. Review commonly asked questions about classification, pregnancy, recurrence and mutation types. This is a great resource for newly-diagnosed patients.

The DTRF and desmoid tumors have been highlighted in the media creating greater awareness of the disease. Patients, physicians and board members have played a key role in this effort.